132 related articles for article (PubMed ID: 38671580)
1. An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer.
Fleischer T; Haugen MH; Ankill J; Silwal-Pandit L; Børresen-Dale AL; Hedenfalk I; Hatschek T; Tost J; Engebraaten O; Kristensen VN
Mol Oncol; 2024 Apr; ():. PubMed ID: 38671580
[TBL] [Abstract][Full Text] [Related]
2. DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer.
Gampenrieder SP; Rinnerthaler G; Hackl H; Pulverer W; Weinhaeusel A; Ilic S; Hufnagl C; Hauser-Kronberger C; Egle A; Risch A; Greil R
Theranostics; 2018; 8(8):2278-2288. PubMed ID: 29721079
[No Abstract] [Full Text] [Related]
3. miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer.
Lindholm EM; Ragle Aure M; Haugen MH; Kleivi Sahlberg K; Kristensen VN; Nebdal D; Børresen-Dale AL; Lingjaerde OC; Engebraaten O
Mol Oncol; 2019 Oct; 13(10):2278-2296. PubMed ID: 31402562
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival.
Pedersen CA; Cao MD; Fleischer T; Rye MB; Knappskog S; Eikesdal HP; Lønning PE; Tost J; Kristensen VN; Tessem MB; Giskeødegård GF; Bathen TF
Breast Cancer Res; 2022 Jun; 24(1):43. PubMed ID: 35751095
[TBL] [Abstract][Full Text] [Related]
5. Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations.
Höglander EK; Nord S; Wedge DC; Lingjærde OC; Silwal-Pandit L; Gythfeldt HV; Vollan HKM; Fleischer T; Krohn M; Schlitchting E; Borgen E; Garred Ø; Holmen MM; Wist E; Naume B; Van Loo P; Børresen-Dale AL; Engebraaten O; Kristensen V
Genome Med; 2018 Nov; 10(1):92. PubMed ID: 30497530
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide DNA methylation signature predict clinical benefit of bevacizumab in non-small cell lung cancer.
Li B; Jiang C; Xu Y; Fan X; Yang L; Zou B; Fan B; Wang L
BMC Cancer; 2022 Jul; 22(1):828. PubMed ID: 35906610
[TBL] [Abstract][Full Text] [Related]
7. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
[TBL] [Abstract][Full Text] [Related]
8. Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers.
Haugen MH; Lingjærde OC; Hedenfalk I; Garred Ø; Borgen E; Loman N; Hatschek T; Børresen-Dale AL; Naume B; Mills GB; Mælandsmo GM; Engebraaten O
JCO Precis Oncol; 2021; 5():. PubMed ID: 34036235
[TBL] [Abstract][Full Text] [Related]
9. The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer.
Silwal-Pandit L; Nord S; von der Lippe Gythfeldt H; Møller EK; Fleischer T; Rødland E; Krohn M; Borgen E; Garred Ø; Olsen T; Vu P; Skjerven H; Fangberget A; Holmen MM; Schlitchting E; Wille E; Nordberg Stokke M; Moen Vollan HK; Kristensen V; Langerød A; Lundgren S; Wist E; Naume B; Lingjærde OC; Børresen-Dale AL; Engebraaten O
Clin Cancer Res; 2017 Aug; 23(16):4662-4670. PubMed ID: 28487444
[No Abstract] [Full Text] [Related]
10. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.
Bertucci F; Fekih M; Autret A; Petit T; Dalenc F; Levy C; Romieu G; Bonneterre J; Ferrero JM; Kerbrat P; Soulie P; Mouret-Reynier MA; Bachelot T; Lerebours F; Eymard JC; Deblock M; Lortholary A; Hardy-Bessard AC; Barthelemy P; Bonnefoi H; Charafe-Jauffret E; Bidard FC; Viens P; Lemonnier J; Pierga JY
Lancet Oncol; 2016 May; 17(5):600-11. PubMed ID: 27032301
[TBL] [Abstract][Full Text] [Related]
12. Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial.
Kimbung S; Markholm I; Bjöhle J; Lekberg T; von Wachenfeldt A; Azavedo E; Saracco A; Hellström M; Veerla S; Paquet E; Bendahl PO; Fernö M; Bergh J; Loman N; Hatschek T; Hedenfalk I;
Int J Cancer; 2018 Feb; 142(3):618-628. PubMed ID: 28940389
[TBL] [Abstract][Full Text] [Related]
13. Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314.
Lu YT; Plets M; Morrison G; Cunha AT; Cen SY; Rhie SK; Siegmund KD; Daneshmand S; Quinn DI; Meeks JJ; Lerner SP; Petrylak DP; McConkey D; Flaig TW; Thompson IM; Goldkorn A
Eur Urol Oncol; 2023 Oct; 6(5):516-524. PubMed ID: 37087309
[TBL] [Abstract][Full Text] [Related]
14. Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancer.
von der Lippe Gythfeldt H; Lien T; Tekpli X; Silwal-Pandit L; Borgen E; Garred Ø; Skjerven H; Schlichting E; Lundgren S; Wist E; Naume B; Kristensen V; Børresen-Dale AL; Lingjaerde OC; Engebraaten O
Int J Cancer; 2020 Nov; 147(9):2515-2525. PubMed ID: 32488909
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers.
Nome ME; Euceda LR; Jabeen S; Debik J; Bathen TF; Giskeødegård GF; Taskén KA; Maelandsmo GM; Halvorsen B; Yndestad A; Borgen E; Garred Ø; Aukrust P; Ueland T; Engebraaten O; Kristensen VN; Tekpli X
Int J Cancer; 2020 Jan; 146(1):223-235. PubMed ID: 31444972
[TBL] [Abstract][Full Text] [Related]
16. A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients.
Pineda B; Diaz-Lagares A; Pérez-Fidalgo JA; Burgués O; González-Barrallo I; Crujeiras AB; Sandoval J; Esteller M; Lluch A; Eroles P
Clin Epigenetics; 2019 Feb; 11(1):33. PubMed ID: 30786922
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of neoadjuvant chemotherapy combined with bevacizumab versus neoadjuvant chemotherapy alone for Her2-negative breast cancer: a meta-analysis of randomized controlled clinical trials].
Han R; Wang G; Zhang Y; Zhao X
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2016 May; 45(4):379-386. PubMed ID: 27868411
[TBL] [Abstract][Full Text] [Related]
18. Integrated multi-omics profiling of high-grade estrogen receptor-positive, HER2-negative breast cancer.
Wang K; Li L; Franch-Expósito S; Le X; Tang J; Li Q; Wu Q; Bassaganyas L; Camps J; Zhang X; Li H; Foukakis T; Xiang T; Wu J; Ren G
Mol Oncol; 2022 Jun; 16(12):2413-2431. PubMed ID: 34146382
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer.
Lim SH; Cho HJ; Kim KM; Lim HY; Kang WK; Lee J; Park YS; Kim HC; Kim ST
Oncol Res; 2023; 31(6):855-866. PubMed ID: 37744267
[TBL] [Abstract][Full Text] [Related]
20. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
Wagner AD; Thomssen C; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
